|By PR Newswire||
|April 25, 2014 06:30 PM EDT||
CHAPEL HILL, N.C., April 25, 2014 /PRNewswire/ -- The pharmaceutical industry's relatively lackluster pipeline is pushing strategy and development executives to look for opportunities for sustainable growth.
One opportunity lies in combination therapies with branded products to extend patent life. For pharma companies, fixed dose combination (FDC) products can extend a therapeutic advantage and become part of lifecycle management. For the patient, FDC products can address unmet medical needs and reduce pill burdens.
While FDC products can have clinical and commercial advantages, they also can be challenging to bring to market. A Best Practices, LLC report found it takes between five and eight years and an average of $80 million to bring a FDC product to market. One of the keys to successfully commercializing a FDC therapy is to create a differentiated product with a therapeutic benefit, according to the study.
Indeed, critical product-shaping strategies such as positioning and value were tactics that veteran FDC leaders identified as most valuable for a successful launch of a FDC product, according to "Fixed Dose Combination Products: Successful Strategies for Developing and Bringing FDC Products to Market." As one R&D veteran noted in the report, "Bring some value to the payers. If a payer looks at it and there's not really any kind of clinical differentiation, whether it's better efficacy, speed of onset, better response, or better remission, the payers tell us very, very clearly that they're not interested."
Some of the issues addressed in this research include:
- Chief reason for pursuing FDC development
- Measures used to evaluate success
- Years from decision to develop through launch
- Approximate cost of FDC product development
- Difficulty areas for bringing FDC product to market
- Reasons for partnering with another company to develop FDC product
- Time lapsed from initial contact to signed contractual agreement with partner
- U.S. filing routes used
- EU filing routes used
- Months from filing to approval
- Pre-launch marketing challenges
- Strategies, tactics, practices to help accelerate or impede launch progress
The full 55-page report contains more than 150 benchmark metrics, providing executives with the tools, tactics and techniques to help organizations successfully develop and commercialize fixed dose combination products. Review a complimentary summary of the study at http://www3.best-in-class.com/rr1285.htm. The summary includes selected best practices drawn from extensive primary research with 51 representatives from 34 leading companies, including eight of the Top 20 pharma companies.
ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.
SOURCE Best Practices, LLC
Verizon Communications Inc. (NYSE, Nasdaq: VZ) and Yahoo! Inc. (Nasdaq: YHOO) have entered into a definitive agreement under which Verizon will acquire Yahoo's operating business for approximately $4.83 billion in cash, subject to customary closing adjustments. Yahoo informs, connects and entertains a global audience of more than 1 billion monthly active users** -- including 600 million monthly active mobile users*** through its search, communications and digital content products. Yahoo also co...
Jul. 26, 2016 02:30 PM EDT Reads: 458
Ixia (Nasdaq: XXIA) has announced that NoviFlow Inc.has deployed IxNetwork® to validate the company’s designs and accelerate the delivery of its proven, reliable products. Based in Montréal, NoviFlow Inc. supports network carriers, hyperscale data center operators, and enterprises seeking greater network control and flexibility, network scalability, and the capacity to handle extremely large numbers of flows, while maintaining maximum network performance. To meet these requirements, NoviFlow in...
Jul. 26, 2016 02:00 PM EDT Reads: 514
As companies gain momentum, the need to maintain high quality products can outstrip their development team’s bandwidth for QA. Building out a large QA team (whether in-house or outsourced) can slow down development and significantly increases costs. This eBook takes QA profiles from 5 companies who successfully scaled up production without building a large QA team and includes: What to consider when choosing CI/CD tools How culture and communication can make or break implementation
Jul. 26, 2016 02:00 PM EDT Reads: 1,620
Jul. 26, 2016 01:45 PM EDT Reads: 1,989
Jul. 26, 2016 12:30 PM EDT Reads: 1,579
Jul. 26, 2016 11:45 AM EDT Reads: 549
Jul. 26, 2016 10:45 AM EDT Reads: 1,719
Jul. 26, 2016 10:37 AM EDT Reads: 302
Jul. 26, 2016 10:15 AM EDT Reads: 1,179
Jul. 26, 2016 10:00 AM EDT Reads: 989
Jul. 26, 2016 09:45 AM EDT Reads: 947
Jul. 26, 2016 09:45 AM EDT Reads: 768
Jul. 26, 2016 09:45 AM EDT Reads: 337
Jul. 26, 2016 09:30 AM EDT Reads: 1,093
Jul. 26, 2016 09:15 AM EDT Reads: 1,013